Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Micafungin
Drug ID BADD_D01455
Description Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
Indications and Usage For use in the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis.
Marketing Status Prescription
ATC Code J02AX05
DrugBank ID DB01141
KEGG ID D08218
MeSH ID D000077551
PubChem ID 477468
TTD Drug ID D06TOE
NDC Product Code 60505-6119; 42023-229; 42023-230; 60505-6120
Synonyms Micafungin | FK 463 | FK463 | FK-463 | Micafungin Sodium | Mycamine
Chemical Information
Molecular Formula C56H71N9O23S
CAS Registry Number 235114-32-6
SMILES CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC (=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)C(C C(=O)N)O)C)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vasculitis24.05.02.001; 10.02.02.0060.000705%
Vomiting07.01.07.003--
White blood cell count decreased13.01.06.012--
Acute generalised exanthematous pustulosis23.03.10.002; 12.03.01.0050.000705%Not Available
Deep vein thrombosis24.01.02.003--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Infusion related reaction12.02.05.009; 10.01.01.017; 08.01.03.002--
Lymphatic disorder01.09.01.003--Not Available
Foetor hepaticus07.01.06.026; 09.01.05.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Candida sepsis11.03.03.0170.000705%Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.0010.001057%Not Available
Febrile bone marrow aplasia08.05.02.005; 01.03.03.0070.001057%Not Available
Klebsiella sepsis11.02.03.0020.000705%Not Available
Escherichia bacteraemia11.02.10.0010.001410%Not Available
Transaminases increased13.03.01.015--Not Available
Infusion site inflammation12.07.05.020; 08.02.05.020--Not Available
Toxic skin eruption23.03.05.003; 10.01.01.0080.001410%Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Drug resistance08.06.01.0050.000919%Not Available
Hepatic enzyme increased13.03.01.0190.000705%Not Available
Cardiac disorder02.01.01.003--Not Available
Connective tissue disorder15.06.01.006--Not Available
Infestation23.09.05.001; 11.09.01.001--Not Available
Inflammation08.01.05.007--Not Available
Malnutrition14.03.02.004--Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages